Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06824454
PHASE2
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
Sponsor: Stanford University
View on ClinicalTrials.gov
Summary
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-03
Completion Date
2026-03
Last Updated
2025-02-13
Healthy Volunteers
No
Conditions
Interventions
DRUG
Dipyridamole 75 MG
Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.
Locations (1)
Stanford University
Stanford, California, United States